AFT gets first step of US approval for Maxigesic IV

Sophie Boot
Wed, 23 Mar 2016

By Sophie Boot March 24 (BusinessDesk) - AFT Pharmaceuticals has crossed the first hurdle in getting the intravenous version of its patented combination painkiller Maxigesic approved by the US Food and Drug Administration. The investigational new drug application (IND) for Maxigesic IV has been approved by the FDA, which is the first step towards getting approval in the US, the Auckland-based drugmaker said in a statement. It will now conduct a clinical study in Christchurch, followed by one in the US, as part of the path to gaining appro...
MARKET CLOSE: NZ shares rise as optimism over covid drug buoys Asia
Dan Brunskill | Mon, 13 Jul 2020

New Zealand shares joined a rally across Asia, as upbeat investor sentiment spilled over from Wall Street's close on Friday on optimism over a late-stage trial for a hopeful covid-19 treatment.  Th...

Law & Regulation
SFO probes Labour Party on donations
Victoria Young | Mon, 13 Jul 2020

The Serious Fraud Office has confirmed a fifth investigation into electoral funding, stating today it is looking into donations to the Labour Party.The agency said the probe relates to donations made...

NZ dollar little changed as global shares defy worsening covid news
Jenny Ruth | Mon, 13 Jul 2020

The New Zealand dollar was little changed as traders awaited further trend-setting information and as rising share markets were offset by Florida reporting a US record for new covid infections. The...

The role of private equity in the wake of COVID-19

As local covid-19 restrictions ease, a new business cycle is beginning in New Zealand.